Altimmune Inc

In the Stage 4 decline, ALT remains in a lower-high/lower-low sequence below all major EMAs. Price action is sideways and indecisive around the 9/21 EMA band with RSI neutral. Medium-term structure is bearish while the long-term trend stays up. Execution calls for trimming into rallies up to the EMA resistance zone.

• ↑Secured $535M cash runway to support Phase 3 MASH trials through 2029
• ↑59.1% of subjects achieved MASH resolution at 24 weeks in Pembedutide trial
• ↓Earnings yield remains negative and profitability metrics are weak